323 related articles for article (PubMed ID: 34131208)
21. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
23. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
24. Histological spatial analysis on the induction of PD-L1
Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
[TBL] [Abstract][Full Text] [Related]
25. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
26. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Ahmed FS; Gaule P; McGuire J; Patel K; Blenman K; Pusztai L; Rimm DL
Clin Cancer Res; 2020 Oct; 26(20):5456-5461. PubMed ID: 32709714
[TBL] [Abstract][Full Text] [Related]
28. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
29. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
30. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
31. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L; Slagter M; Horlings HM; Sikorska K; van de Vijver KK; de Maaker M; Nederlof I; Kluin RJC; Warren S; Ong S; Wiersma TG; Russell NS; Lalezari F; Schouten PC; Bakker NAM; Ketelaars SLC; Peters D; Lange CAH; van Werkhoven E; van Tinteren H; Mandjes IAM; Kemper I; Onderwater S; Chalabi M; Wilgenhof S; Haanen JBAG; Salgado R; de Visser KE; Sonke GS; Wessels LFA; Linn SC; Schumacher TN; Blank CU; Kok M
Nat Med; 2019 Jun; 25(6):920-928. PubMed ID: 31086347
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer.
Zheng S; Zou Y; Xie X; Liang JY; Yang A; Yu K; Wang J; Tang H; Xie X
Int J Cancer; 2020 Jul; 147(2):542-553. PubMed ID: 32285442
[TBL] [Abstract][Full Text] [Related]
33. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
34. Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes.
Liu M; Li C; Qu J; Sun S; Zhao Z; Wang W; Lv W; Zhang Y; Cai Y; Zhao F; Wu F; Zhang S; Zhao X
Cancer Sci; 2023 Oct; 114(10):3834-3847. PubMed ID: 37489486
[TBL] [Abstract][Full Text] [Related]
35. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
38. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
[TBL] [Abstract][Full Text] [Related]
39. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
40. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]